DEVELOPING SYNERGISTIC THERAPEUTIC STRATEGY TO UNCOVER ENHANCED ANTI-TUMOR EFFICACY IN HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)

Background: The most deadly gynecological malignancy has a late-stage diagnosis, fast progress, and recurrence, called high-grade serous ovarian carcinoma (HGSOC). The clinical conclusion now requires innovative therapeutic approaches. Objectives: In this study, the anticancer properties of chlorpromazine (CPZ), an antipsychotic, and metformin, an anti-diabetic, were investigated to determine their potential for synergistic therapeutic approaches in HGSOC. Methodology: In vitro assays using the ovarian carcinoma 3 (OVCAR3) cell line significantly reduced cell viability and proliferation in the CPZ + metformin group compared to either alone. The combination of CPZ and metformin demonstrated significant effectiveness during the initial stages of treatment against ovarian cancer cell lines. Results: In early-phase assays, both agents showed synergistic effects, resulting in greater inhibition of cancer cell proliferation than with individual treatments. The initial response included marked reductions in cell viability and suppressed colony formation, indicating that the CPZ-metformin combination holds strong potential as an effective early intervention strategy in ovarian cancer therapy. After drug treatment, hemocytometer and clonogenic assay were used to assess cell viability and colony-forming count, respectively, to define the single- and combined-drug impact; then, molecular analysis was performed using conventional PCR, and the data were analysed by gel electrophoresis. Conclusion: The synergistic system enhanced anti-tumor efficacy and also justifies drug repurposing in ovarian cancer treatment.